Hemofiltrate C-C chemokine (HCC)-1 is a recently cloned C-C chemokine that is structurally similar to macrophage inflammatory protein (MIP)-1α. Unlike most chemokines, it is constitutively secreted by tissues and is present at high concentrations in normal human plasma. Also atypical for chemokines, HCC-1 is reported not to be chemotactic for leukocytes. In this paper, we have investigated the chemokine receptor usage and downstream signaling pathways of HCC-1. Cross-desensitization experiments using THP-1 cells suggested that HCC-1 and MIP-1α activated the same receptor. Experiments using a panel of cloned chemokine receptors revealed that HCC-1 specifically activated C-C chemokine receptor (CCR)1, but not closely related receptors, including CCR5. HCC-1 competed with MIP-1α for binding to CCR1-transfected cells, but with a markedly reduced affinity (IC50 = 93 nM versus 1.3 nM for MIP-1α). Similarly, HCC-1 was less potent than MIP-1α in inducing inhibition of adenylyl cyclase in CCR1-transfected cells. HCC-1 induced chemotaxis of freshly isolated human monocytes, THP-1 cells, and CCR1-transfected cells, and the optimal concentration for cell migration (100 nM) was ∼100-fold lower than that of MIP-1α (1 nM). These data demonstrate that HCC-1 is a chemoattractant and identify CCR1 as a functional HCC-1 receptor on human monocytes.
Skip Nav Destination
Article navigation
3 August 1998
Brief Definitive Report|
August 03 1998
Identification of C-C Chemokine Receptor 1 (CCR1) as the Monocyte Hemofiltrate C-C Chemokine (HCC)-1 Receptor
Chia-Lin Tsou,
Chia-Lin Tsou
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
Ron P. Gladue,
Ron P. Gladue
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
Laurie A. Carroll,
Laurie A. Carroll
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
Tim Paradis,
Tim Paradis
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
James G. Boyd,
James G. Boyd
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
Robin T. Nelson,
Robin T. Nelson
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
Kuldeep Neote,
Kuldeep Neote
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
Israel F. Charo
Israel F. Charo
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Search for other works by this author on:
Chia-Lin Tsou
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Ron P. Gladue
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Laurie A. Carroll
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Tim Paradis
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
James G. Boyd
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Robin T. Nelson
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Kuldeep Neote
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Israel F. Charo
From the *Gladstone Institute of Cardiovascular Disease, the Cardiovascular Research Institute, the ‡Daiichi Research Center, and the Department of Medicine, University of California, San Francisco, California 94141; and §Pfizer Inc., Groton, Connecticut 06340
Address correspondence to Israel F. Charo, Gladstone Institute of Cardiovascular Disease, PO Box 419100, San Francisco, CA 94141-9100. Phone: 415-826-7500; Fax: 415-285-5632; E-mail: [email protected]
Received:
February 06 1998
Revision Received:
April 10 1998
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1998
J Exp Med (1998) 188 (3): 603–608.
Article history
Received:
February 06 1998
Revision Received:
April 10 1998
Citation
Chia-Lin Tsou, Ron P. Gladue, Laurie A. Carroll, Tim Paradis, James G. Boyd, Robin T. Nelson, Kuldeep Neote, Israel F. Charo; Identification of C-C Chemokine Receptor 1 (CCR1) as the Monocyte Hemofiltrate C-C Chemokine (HCC)-1 Receptor . J Exp Med 3 August 1998; 188 (3): 603–608. doi: https://doi.org/10.1084/jem.188.3.603
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement